NDATOPICALFOAM
Approved
Dec 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Phosphodiesterase 4 Inhibitors
Pharmacologic Class:
Phosphodiesterase 4 Inhibitor
Clinical Trials (5)
A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients
Started Mar 2016
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
Started May 2014
1,323 enrolled
Chronic Obstructive Pulmonary Disease (COPD)
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
Started Mar 2014
20 enrolled
Schizophrenia
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
Started Jan 2014
27 enrolled
Memory ImpairmentAlzheimer's Disease
Long-term Observational Study of the Safety of Roflumilast
Started Dec 2013
135,856 enrolled
COPD
Loss of Exclusivity
LOE Date
Aug 19, 2042
200 months away
Patent Expiry
Aug 19, 2042
Exclusivity Expiry
May 22, 2028